Your session is about to expire
← Back to Search
JNJ-75229414 for Prostate Cancer
Study Summary
This trial is testing a new cancer drug to see what the best dosage is and if it is safe.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have experienced severe immune or nerve side effects from previous cancer treatment.My cancer can be measured by scans or has detectable PSA levels.I haven't had systemic treatment for cancer, other than prostate cancer, in the last 6 months.I haven't had certain cancer treatments in the last 2-3 weeks.I have previously been treated with specific prostate cancer medications or chemotherapy.I agree to use a condom and spermicide during sex for 1 year after my last treatment dose.I am fully active or can carry out light work.I have previously received CAR-T cell therapy.My prostate cancer has spread, and it's confirmed to be adenocarcinoma.I have previously received treatment targeting KLK2.I have previously been treated with specific prostate cancer medications or chemotherapy.
- Group 1: Part 1: Dose Escalation
- Group 2: Part 2: Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research project recruiting participants at this time?
"According to clinicaltrials.gov, the search for participants is still ongoing since its initial listing on September 28th 2021 and last update on November 22nd 2022."
What primary endpoints is this clinical trial attempting to identify?
"This clinical trial, which will run for a maximum of 28 days, aims to quantify the number of adverse events (AEs) according to severity. Secondary objectives include measuring Area Under Plasma Concentration Versus Time Curve from Time Zero to t Time (AUC[0-t]), ascertaining the presence of Anti-JNJ-75229414 Antibodies in participants, and calculating Overall Response Rate (ORR), with Prostate cancer Working Group 3 (PCWG3) criteria being applied when assessing progressive bone metastases."
What potential adverse effects are associated with JNJ-75229414 administration?
"JNJ-75229414 is a still in initial testing, so it was assigned a safety rating of 1. This Phase 1 trial has very little data to support its efficacy and safety efficacy."
What is the scope of individuals involved in this experiment?
"Indeed, according to information sourced from clinicaltrials.gov, this experiment is currently recruiting subjects. The trial was first published on September 28th 2021 and recently updated on November 22nd 2022. There are 10 different sites looking for 40 participants alltogether."
To what extent has this clinical trial been implemented in medical facilities?
"This trial is currently running in 10 distinct locations. Among them are New york, West Hollywood and Salt Lake City as well as an additional 7 sites. To reduce travel demands, it is suggested to choose the closest one if you decide to enroll in the study."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger